TD Cowen analyst Tyler Van Buren has maintained their bullish stance on MBX stock, giving a Buy rating today.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Tyler Van Buren has given his Buy rating due to a combination of factors related to MBX’s advancing pipeline and upcoming data catalysts in obesity and hypoparathyroidism. He views the imminent blinded Phase I obesity data for MBX‑4291 as an important validation point for the company’s prodrug platform, with pharmacokinetic and safety readouts expected to support the differentiated profile seen in non‑human primates and set the stage for more meaningful efficacy results later this year.
In addition, he highlights the approaching 52‑week open‑label extension data for canvuparatide in hypoparathyroidism, which should reinforce a favorable safety and efficacy profile relative to the benchmark established by Yorvi’s label. Together with the on‑schedule Phase III canvu program, potential obesity pipeline updates such as an amycretin nomination, and the involvement of respected scientific leadership, these milestones underpin his confidence in MBX’s long‑term value creation and support a positive stance on the stock.
Van Buren covers the Healthcare sector, focusing on stocks such as Moderna, Crispr Therapeutics AG, and Spyre Therapeutics. According to TipRanks, Van Buren has an average return of 27.5% and a 55.56% success rate on recommended stocks.
In another report released today, LifeSci Capital also maintained a Buy rating on the stock with a $75.00 price target.